Evidence map›Paper›PMID 20485174›Full record

ReviewCurrent opinion in rheumatology2010

Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.

Charles S Via

Abstract readReview
In one paragraph

Review in Current opinion in rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Lupus and Epstein-Barr.Current opinion in rheumatology · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Charles S ViaPathology Department, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA. cvia@usuhs.mil

Funding

IMMUNOPATHOGENESIS OF LUPUSR01AI047466 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI VIA, CHARLES S. · 2001 to 2012
$3.2M
Immunopathogenesis of LupusR56AI047466 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI VIA, CHARLES S. · 2014 to 2014
$189k
NIAID NIH HHS AI047466NIAID NIH HHS R01 AI047466NIAID NIH HHS R56 AI047466
6 · The paper itself

Abstract

purpose of reviewThe central role of CD4 T cells in lupus pathogenesis is well recognized; however, the mechanism by which CD4 T cells lose tolerance and promote humoral autoimmunity remains unclear. This review examines mechanisms elucidated in the parent-into-F1 model of lupus and their possible parallels in human lupus pathogenesis. RECENT

findingsIn the parent-into-F1 model, lupus results from the transfer of normal, foreign reactive CD4 T cells targeted to intrinsically normal F1 B cells. Transfer of normal CD8 T cells prevents lupus, whereas transfer of CD8 T cells with killing defects does not but is correctable with additional in-vivo enhancement of CD8 cytotoxic T lymphocyte (CTL) function. The parent-into-F1 model has two major similarities to Epstein-Barr virus infection: CD4 T-cell-driven polyclonal B-cell hyperactivity and a critical dependence on CD8 CTL for elimination of activated B cells. These similarities are discussed in relation to human lupus pathogenesis. SUMMARY: Work in the parent-into-F1 model supports the idea that lupus may result from defective CD8 T-cell function and that therapeutic enhancement of CD8 effectors with selective targeting to autoreactive B cells may be beneficial. Despite strong evidence linking Epstein-Barr virus infection with human lupus, the exact nature of this link requires further study.

Indexed as

AutoimmunityGraft vs Host DiseaseHerpesvirus 4, HumanHumansLupus Erythematosus, SystemicLymphocyte ActivationT-Lymphocytes, Cytotoxic

Identifiers

PMID20485174
PMCPMC3204365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.